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Abstract
Introduction Rapid detection of Shiga toxin-producing
Escherichia coli (STEC) enables appropriate treatment.
Numerous commercially available molecular tests exist,
but they vary in clinical performance. This systematic
review aims to synthesise available evidence to compare
the clinical performance of enzyme immunoassay (EIA) and
nucleic acid amplification tests (NAATs) for the detection
of STEC.
Methods and analysis The following databases will
be searched employing a standardised search strategy:
Medline, Embase, Cochrane CENTRAL Register of
Controlled Trials, Cochrane Database of Systematic
Reviews, PubMed, Scopus and Web of Science. Grey
literature will be searched under advice from a medical
librarian. Independent reviewers will screen titles,
abstracts and full texts of retrieved studies for relevant
studies. Data will be extracted independently by two
reviewers, using a piloted template. Quality Assessment
of Diagnostic Accuracy Studies-2 will be employed to
assess the risk of bias of individual studies, and the
quality of evidence will be assessed with the Grading
of Recommendations Assessment, Development and
Evaluation approach. A bivariate random-effects model
will be used to meta-analyse the sensitivity and specificity
of commercial STEC diagnostic tests, and a hierarchical
summary receiver operator characteristic curve will
be constructed. Studies of single test accuracy of EIA
and NAATs and studies of comparative accuracy will be
analysed separately.
Ethics and dissemination Ethics approval was not
required for this systematic review and meta-analysis.
Findings will be disseminated in conferences, through a
peer-reviewed journal and via personal interactions with
relevant stakeholders.
PROSPERO registration number CRD42018099119.

Introduction
Shiga toxin-producing Escherichia coli (STEC)
cause significant disease. Although prototypical E. coli O157:H7 is the leading cause
of haemolytic uraemic syndrome (HUS),

Strengths and limitations of this study
►► There is little evidence reviewing the relative clini-

cal performance of commercially available tests for
Shiga toxin-producing Escherichia coli (STEC).
►► A key strength of this study is the comprehensive
comparison of enzyme immunoassays and nucleic
acid amplification tests to inform clinical practice.
►► A limitation is the lack of a common gold standard
for STEC identification, which may introduce heterogeneity into our analysis.
►► Another limitation is that the finding of a Shiga toxin
(Stx) 1 producing STEC that does not also produce
Stx2, especially in the absence of bloody diarrhoea,
is of unclear clinical and epidemiological value.

other STEC serotypes have been associated
with severe disease and large outbreaks.1–4
Multiple serotypes have now been linked to
disease. Unlike the O157 serotype, detection of non-O157 serotypes has increased
significantly in the past decade, though likely
because of dissemination of technology to
detect these organisms.5 Patients infected
with STEC often seek care through emergency departments (EDs), especially if they
have bloody diarrhoea. Strong evidence
suggests that antibiotics may increase the
risk of developing HUS if administered
to people infected with STEC,6–8 and a
recent meta-analysis demonstrated that the
early administration of fluids is associated
with improved outcomes.9 Therefore, it is
important that healthcare providers have a
means of detecting STEC that is both rapid
and applicable to any serotype.
Historically, STEC testing has focused on
the O157 serogroup using culture on sorbitol-MacConkey agar, leveraging its inability
to ferment sorbitol.10 This attribute is not
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Methods and analysis
This systematic review and meta-analysis will be conducted
in accordance with reporting requirements for Preferred
Reporting Items for Systematic Reviews and Meta-analyses statement (PRISMA). This protocol was prepared
according to PRISMA-Protocol and PRISMA-DTA guidelines.23 24
Research question
What is the accuracy of commercially available EIA and
NAAT for the detection of STEC and how do they differ?
Eligibility criteria
Participants: study participants with acute diarrhoea,
who provide a stool specimen or rectal swab for diagnostic testing; any age or subpopulation.
►► Setting: healthcare systems or medical facilities,
including outpatient clinics, EDs, hospitals, longterm care centres and similar, without geographical
limitation.
►► Index tests: any commercially available EIA or NAAT
for the detection of Stx, or Stx1 and Stx2; NAAT for
the identification of the O157 serogroup, if available. Included studies may assess the accuracy of
►►

2

►►

►►
►►

►►

commercially available EIA, NAAT or both, including
comparative accuracy studies.
Reference standard: at least one of the following:
enhanced protocols, real-time PCR, sequencing and/
or other NAAT.
Target condition: acute diarrhoea associated with
STEC infection.
Study designs: cross-sectional diagnostic accuracy
studies, encompassing all studies with both index
and reference tests conducted on stool samples/
swabs collected at a single point of time during the
acute diarrhoea illness, including both single test and
comparative accuracy studies.
Report characteristics: years 2005 to present (2015
to present for conference abstracts), published or
unpublished, in any language.

Literature searches
The following databases will be searched from 2005:
MEDLINE, Cochrane CENTRAL Register of Controlled
Trials, Cochrane Database of Systematic Reviews, EMBASE,
PubMed, SCOPUS and Web of Science. Clinical trial databases (
ClinicalTrials.
gov), Food and Drug Administration applications, package inserts for commercial assays,
company product websites and literature, government/
non-governmental organization reports and conference
abstracts will also be searched under the advice of STEC
subject experts and a medical librarian. The reference lists
of included studies will be scanned to identify additional
studies of relevance to this review. The specific search
strategy can be found in online supplementary appendix I.
Study records
Data management
Records retrieved will be uploaded into EndNote
V.8 (Philadelphia, Pennsylvania, USA), and deduplicated
using EndNote V.8 and Rayyan for Systematic Reviews
(Qatar, 2018).
Selection process
Two reviewers (GAMT, CYL) will independently screen
all titles and abstracts in duplicate, and a third reviewer
(SBF) will adjudicate any disagreements. Studies will be
included if the title and abstract indicate that the manuscript may contain data related to the evaluation of EIA
and/or NAAT for the detection of STEC. The full text of
all potentially relevant citations will then be obtained and
reviewed by two independent reviewers (GAMT, CYL)
using the predefined eligibility criteria outlined above,
with the involvement of a third reviewer (SBF) in case
consensus cannot be reached. Reasons for inclusion and
exclusion will be documented. A tool to document the
selection process will be developed, piloted with the first
25 search results and modified as necessary.
Data extraction
Two reviewers will extract data independently and in
duplicate using a structured form. The form will be
piloted on the first five included studies and modified as
Tarr GAM, et al. BMJ Open 2019;9:e025950. doi:10.1136/bmjopen-2018-025950
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shared by other STEC serogroups, so they are overlooked
if sorbitol-MacConkey agar culture is the only detection
method employed. Further, culture can take days to yield
results, delaying informed management.11 In light of the
limitations of culture, enzyme immunoassay (EIA) and
nucleic acid amplification tests (NAATs) have been developed to detect STEC irrespective of serogroup. Reflecting
their popularity, the US Council of State and Territorial
Epidemiologists has recently revised the probable STEC
case definition to include laboratory evidence from EIA
and NAAT.12
Numerous tests to detect STEC are commercially available.13 14 The EIAs detect Shiga toxin (Stx), and most
NAATs detect the Stx genes Stx1 and Stx2, and some
additionally seek a locus that is specific to the O157 serogroup. For NAAT, STEC is often one of several enteropathogens detected by the assay. EIA has suboptimal
sensitivity, particularly if a time-consuming enrichment
step is not conducted.15–18 Commercial NAATs appear to
be more sensitive, but results vary by study and test.19–21
NAATs are more costly than traditional microbiological
techniques owing to the equipment and consumables
required to perform them. However, the higher cost
may be compensated by increased ascertainment21 and/
or improved patient outcomes.22 As laboratories consider
NAATs, it is crucial to identify the best testing strategy to
support time-sensitive, cost-effective treatment decisions.
Thus, we will conduct a systematic review of commercial
EIA and NAAT for STEC detection to determine if and
how their performance differs in terms of diagnostic test
accuracy (DTA).

Open access

Risk of bias assessments
To assess the risk of bias in individual studies, we will employ
the Quality Assessment of Diagnostic Accuracy Studies-2
(QUADAS-2).25 We will follow the recommended process
for tailoring the QUADAS-2 to our systematic review,
including iteratively tailoring the QUADAS-2 assessment
tool and piloting it on at least five studies until consensus
has been reached on a version of the tool.25 As part of
this process, we will review the Standards for Reporting of
Diagnostic Accuracy26 and prior QUADAS-2 modifications
for comparative accuracy studies27 for relevant criteria.
For comparative accuracy studies, we will add a signalling
question regarding the assessment of EIA and NAATs in
the same group of patients. The risk of bias in individual
studies (for all outcomes reported) will be rated as low/
unclear/high.28 Assessments will be made independently
by two reviewers, and disagreements will be resolved by
discussion, or where necessary, by a third reviewer. Risk of
bias will be reported for all included studies.
Data synthesis
Separate synthesis will be conducted for EIA and NAAT.
For each of test type, data will be quantitatively synthesised if at least four studies have been identified. If the
number of included studies for either EIA or NAAT is
insufficient, point estimates and CIs from the individual
papers will be shown, and the comparison of EIA and
NAAT will be based on the range of estimates reported in
individual papers.
If four or more studies are included for a given test
type, a bivariate random-effects model29 will be used to
calculate summary estimates and confidence intervals
of primary outcomes and secondary outcomes, and a
hierarchical summary receiver operating characteristic
(ROC) curve30 will be constructed.31 The summary point
for sensitivity and specificity with confidence ellipse and
the hierarchical summary ROC curve will be graphed.
These analyses take into account the correlation between
sensitivity and specificity and potential threshold effects
(eg, due to cycle thresholds used in PCR).31 Meta-analysis
packages in R32 and RevMan33 will be used to conduct all
analyses.
Comparative accuracy
To compare EIA and NAAT, we will meta-analyse only
comparative accuracy studies that evaluate both types
of the test against the same reference standard. If no
comparative accuracy studies are identified, we will graphically compare point estimates and CIs for sensitivity
and specificity resulting from the separate meta-analysis
of each type of test. If there is adequate consistency in
Tarr GAM, et al. BMJ Open 2019;9:e025950. doi:10.1136/bmjopen-2018-025950

reference standards used to assess single test accuracy, we
will pool EIA and NAAT studies in a single meta-analysis
and include test type as a covariate to test the difference
in accuracy between EIA and NAAT.
Subgroup analysis
To identify study characteristics that may be contributing
to heterogeneity, we will conduct subgroup analyses when
at least four studies are available per subgroup:
►► Funding (industry vs other).
►► Data source (published vs unpublished).
►► Age (<10 years old and <18 years old).
►► Location of care.
►► Diarrhoea duration (<7 days, ≥7 days, not specified).
►► Presence of bloody diarrhoea.
►► Specimen type.
►► Test brand.
►► Test targets.
►► Reference standard.
Other subgroup analyses not prespecified here will be
identified as such in all reports. Subgroup analyses will
illustrate the magnitude of differences in accuracy, and
thus allow readers to interpret whether they are clinically
meaningful. We will obtain statistical evidence of whether
these factors contribute to heterogeneity in the primary
analysis by adding each to the bivariate random-effects
model as a predictor.
A sensitivity analysis excluding studies with a high risk
of bias will be conducted. Additional sensitivity analyses
will be added if other potential biases become apparent
during the review.
Quality of evidence assessment
For the quality of evidence for each test type, two
reviewers, one with clinical and one with methodological
expertise, will independently use the Grading of Recommendations Assessment, Development and Evaluation
approach to assess the quality of evidence for sensitivity
and specificity.34 35 The test will be considered in the
context of how it relates to patient-important outcomes
to assign importance to the consequences of summary
sensitivity and specificity findings (eg, frequency of false
negatives). The domains of study design, limitations/risk
of bias, directness, consistency, precision and publication
bias will be assessed and combined into a summary grade
for all important outcomes of the test. Publication bias
will be assessed based on differences in accuracy reported
in industry-funded versus non-industry-funded studies.
For the comparison of EIA and NAAT, we will use a
similar approach to grade the quality of evidence, with
the same domains as for single test accuracy. Risk of bias
will reflect the modifications we make to QUADAS-2
for comparative accuracy studies. Indirectness will be
affected by the number of comparative accuracy studies
including both EIA and NAAT; if few comparative accuracy studies are identified and the comparison is based on
single test accuracy from different studies, quality will be
downgraded due to indirectness.
3
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necessary. Discordances will be resolved through discussions involving the reviewers and subject matter experts.
First and last study authors will be contacted if data necessary to calculate sensitivity or specificity are absent from
the manuscript. Study characteristics and study outcomes
(table 1) will be extracted from included studies.
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Item
Study characteristics
 Data source

Rationale
Peer-reviewed studies will be distinguished from non-peer-reviewed data for potential
subgroup analysis

 Funding source

Studies funded by diagnostic test companies may be subject to additional bias; potential
subgroup analysis

 Study design

Cross-sectional studies are expected; other study designs will be noted for potential
subgroup analysis

 Population

Population restrictions within the study (eg, by age, HUS status, etc) will be noted for
potential subgroup analysis

 Setting

Country or region; potential subgroup analysis

Clinical data
 Location of care

Primary care versus ED versus hospital, and potentially other; potential subgroup analysis

 Diarrhoea definition

Study definition for diarrhoea (eg, ≥3 episodes in 24 hours) will facilitate comparability
assessment and interpretation

 Diarrhoea duration

Mean/median or restrictions on illness duration at the time of sampling; facilitate
comparability assessment and interpretation

 Specimen type

Stool specimen or rectal swab; potential subgroup analysis

 Bloody diarrhoea

Frequency of bloody diarrhoea; potential subgroup analysis

Test
 Brand name

Ease of reference

 Type

EIA or NAAT for main comparison

 Enrichment

For EIA tests; potential subgroup analysis

 Targets

Toxin versus DNA, STEC-only versus multianalyte; interpretation and potential subgroup
analysis

 Cycle threshold

Cycle cut-off for positivity; facilitate comparability assessment and interpretation

 Comparator/reference
standard

Composite standard with component tests, discrepant analysis with confirmatory tests;
interpretation and potential source of bias

 Specimen comparability

Specimens tested by index and comparator from the same point in time, of the same type;
potential source of bias

Outcomes
 Outcome type

For STEC generally, Shiga toxin 1 vs 2 or O157 vs non-O157; distinguish primary and
secondary outcomes

 No tested

Outcome calculation and interpretation

 No confirmatory tested

Outcome calculation and interpretation

 No of true positives

Outcome calculation

 No of false positives

Outcome calculation

 No of true negatives

Outcome calculation

 No of false negatives

Outcome calculation

 Sensitivity

Primary outcome

 Specificity

Primary outcome

 Single accuracy measures

For example, AUC, diagnostic accuracy, diagnostic OR; secondary outcome

 PPV

Secondary outcome

 NPV

Secondary outcome

 LR+
 LR−

Secondary outcome
Secondary outcome

AUC, area under the curve; ED, emergency department; EIA, enzyme immunoassay; HUS, haemolytic uraemic syndrome; LR, likelihood ratio;
NAAT, nucleic acid amplification test; NPV, negative predictive value; PPV, positive predictive value; STEC, Shiga toxin-producing Escherichia
coli.

4

Tarr GAM, et al. BMJ Open 2019;9:e025950. doi:10.1136/bmjopen-2018-025950

BMJ Open: first published as 10.1136/bmjopen-2018-025950 on 7 March 2019. Downloaded from http://bmjopen.bmj.com/ on 4 April 2019 by guest. Protected by copyright.

Table 1 Data to be extracted from each included study

Open access

Patient and public involvement
This protocol was designed without patient involvement.
Patients were not invited to comment on the systematic
review design and were not consulted to develop patient-relevant outcomes. Patients were not invited to contribute to
the writing or editing of this protocol for readability or
accuracy.

and license their derivative works on different terms, provided the original work is
properly cited, appropriate credit is given, any changes made indicated, and the use
is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.
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